In the United States,<unk>  was approved specifically for treatment of HER2-positive metastatic breast cancer (mBC) in patients who have been treated previously with<unk>  and a taxane (paclitaxel or docetaxel), and who have already been treated for mBC or developed tumor recurrence within six months of adjuvant therapy. Approval was based on the EMILIA study, a phase III clinical trial that compared<unk>  versus capecitabine (Xeloda) plus lapatinib (Tykerb) in 991 people with unresectable, locally advanced or metastatic HER2-positive breast cancer who had previously been treated with<unk>  and taxane chemotherapy. This trial showed improved progression-free survival in patients treated with<unk>  (median 9.6 vs. 6.4 months), along with improved overall survival (median 30.9 vs. 25.1 months) and safety.
Trastuzumab emtansine
Trastuzumab deruxtecan
Trastuzumab/hyaluronidase
Afatinib
Cetuximab
Neratinib
Dasatinib
Loncastuximab tesirine